|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2013
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Tafinlar
|
|
gptkbp:can_be_combined_with
|
gptkb:trametinib
|
|
gptkbp:chemical_formula
|
C23 H22 F3 N3 O2 S
|
|
gptkbp:class
|
gptkb:Atom
|
|
gptkbp:clinical_trial
|
Phase III
COMBI-d
COMBI-v
|
|
gptkbp:clinical_use
|
targeted therapy
|
|
gptkbp:contraindication
|
hypersensitivity to dabrafenib
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:discovery_year
|
gptkb:2008
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dabrafenib
|
|
gptkbp:indication
|
gptkb:Oncology
anaplastic thyroid cancer
|
|
gptkbp:ingredients
|
dabrafenib mesylate
|
|
gptkbp:interacts_with
|
gptkb:CYP2_C9
gptkb:CYP3_A4
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:lifespan
|
8 hours
|
|
gptkbp:marketed_as
|
gptkb:Tafinlar
|
|
gptkbp:mechanism_of_action
|
BRAF inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:provides_guidance_on
|
daily dosing
|
|
gptkbp:research_focus
|
BRAF mutations
biomarkers
melanoma treatment
combination therapies
resistance mechanisms
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
Category D
|
|
gptkbp:side_effect
|
gptkb:Oncology
fatigue
headache
nausea
fever
liver toxicity
rash
cardiac events
pulmonary toxicity
ocular toxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:BRAF_V600_E_mutation
|
|
gptkbp:used_for
|
treatment of melanoma
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:bfsLayer
|
6
|